← All 60 Degrees Pharmaceuticals, INC filings

60 Degrees Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
SXTP
60 Degrees Pharmaceuticals, INC
10-K: 60 Degrees Pharmaceuticals Reports 2024 Results, Focuses on Arakoda Commercialization and Babesiosis Development
60 Degrees Pharmaceuticals details its 2024 financial results and outlines its strategic shift towards commercializing Arakoda and developing treatments for babesiosis.
NASDAQ
SXTP
60 Degrees Pharmaceuticals, INC
10-K: 60 Degrees Pharmaceuticals Details Share Structure and Financials in Annual 10-K Filing
60 Degrees Pharmaceuticals' annual 10-K filing outlines the company's share structure, recent financial activities, and strategic focus on infectious disease therapeutics.